Amitraz IP/BP/EP Pharma Grade API is a formamidine acaricide supplied as a white to pale yellow crystalline powder with the molecular formula C₁₉H₂₃N₃, CAS 33089-61-1, and molecular weight 293.41 g/mol. The product type designation covers the free base, not a salt form, and the material is controlled against the applicable Indian Pharmacopoeia, British Pharmacopoeia, and European Pharmacopoeia monographs. Amitraz is practically insoluble in water, with a reported aqueous solubility of 1 mg/L at 25 °C and a log P of 5.5. These physicochemical properties impose specific requirements on particle-size reduction, wetting, dispersion, and solvent selection when the API is formulated into tablet, capsule, granule, oral liquid, or injectable dosage forms.

The pharma-grade material is recrystallized and vacuum-dried to control residual process solvents and hydrolytic degradants. The principal degradants monitored by HPLC are 2,4-dimethylaniline and N-(2,4-dimethylphenyl)-N'-methylformamidine, both of which form through hydrolysis of the formamidine bridge. Unlike agricultural technical-grade amitraz, the IP/BP/EP grade carries tighter acceptance limits for related substances, sulfated ash, residual solvents, bacterial endotoxins, and particulate matter. The distinction is critical for oral and parenteral dosage forms because solvent residues and insoluble particulates are not acceptable under Ph Eur general monograph 2034, Ph Eur 5.4, and ICH Q3C.

Pharmacopoeial Monograph Alignment and Release Analytics

The API is released against a compendial panel. The table summarizes typical release criteria; exact acceptance limits in the current monograph may differ according to the national compendium and supplier validation.

The reversed-phase HPLC method separates amitraz from the two principal hydrolytic degradants and other process impurities. System suitability requires resolution between amitraz and the nearest eluting specified impurity, with repeatability verified against the current pharmacopoeial reference standard. Batch-to-batch variance in residual solvent profile is minimized by recrystallization from a defined solvent system and terminal vacuum drying; each batch is nevertheless tested because solvent retention can vary with drying-load geometry and vacuum profile.

Because amitraz is hydrophobic and poorly wettable, blending with aqueous or hydroalcoholic granulating fluids can produce a non-uniform drug distribution unless the API is first dispersed with a suitable wetting agent. The preferred preparation routes are dry granulation or solvent-based granulation using ethanol or isopropanol. Direct compression is feasible only after deagglomeration and addition of a glidant such as colloidal silicon dioxide at 0.1–0.5 % w/w.

What processing constraints arise when amitraz is compacted into tablet or capsule matrices?

Amitraz’s low aqueous solubility and log P 5.5 create a dissolution-rate-limited scenario for oral solid dosage forms. Micronization to D₉₀ below 20 µm improves surface area and content uniformity, but over-micronization can increase electrostatic adhesion and agglomeration. Development batches require evaluation of content uniformity per Ph Eur 2.9.40 and dissolution in a qualified apparatus such as Ph Eur 2.9.3. Published comparative data for amitraz tablet dissolution are limited, so formulation-specific media and sink conditions must be verified rather than assumed from other poorly soluble actives.

Wet granulation with water is constrained by the hydrolysis equilibrium of the formamidine bridge. Forced degradation studies indicate that amitraz hydrolyzes in acidic aqueous media to 2,4-dimethylaniline and N-(2,4-dimethylphenyl)-N'-methylformamidine. If aqueous granulation cannot be avoided, the binder solution should be buffered to a pH above 5.0, and drying temperature should remain below 60 °C. Granules must be assayed for both degradants before compression because hydrolytic impurity formation may continue during storage if moisture is not adequately removed.

On production-scale bin blenders with capacities of 300–1200 L, low-dose amitraz formulations may show segregation if the API is not geometrically diluted. A standard sequence is trituration with lactose monohydrate or microcrystalline cellulose before main blending. Final blend uniformity is assessed by sampling at not fewer than ten locations; relative standard deviation above 5 % warrants reblending or particle-size adjustment. Tablet compression on rotary presses with precompression is used to prevent capping when high fines are generated. Tablet crushing resistance and friability are tested per Ph Eur 2.9.8 and Ph Eur 2.9.7.

For hard capsule filling, hydrophobic amitraz powder can adhere to dosator or tamping pins in high-speed automatic machines. Addition of 0.25–0.5 % sodium stearyl fumarate or 0.1–0.3 % colloidal silicon dioxide reduces sticking and improves flow. Fill weight uniformity is monitored per Ph Eur 2.9.5, and content uniformity is confirmed per Ph Eur 2.9.40.

For oral granule presentations, the API is dispersed on a soluble carrier by fluid-bed granulation using non-aqueous binders, such as hydroxypropyl cellulose in ethanol, or by aqueous binder systems with pH control. The granules are dried to a loss on drying below 2.0 % and sieved to a defined size range, often 150–850 µm. Granule flow, bulk density, and tapped density are measured because they affect sachet filling and reconstitution behavior.

When oral or injectable dosage forms demand control of the formamidine hydrolysis equilibrium

Injectable dosage forms present stringent requirements because amitraz is practically insoluble in water. Water-free or co-solvent vehicles are required to achieve the target concentration. Published data on parenteral amitraz is limited; therefore, vehicle selection requires preformulation screening of solubility, precipitation upon dilution, and chemical stability. The selected vehicle must be of parenteral grade, with controlled peroxide and aldehyde content, and must not promote precipitation upon injection or dilution in physiological fluids.

Bacterial endotoxin and particulate matter are controlled by the drug product manufacturing route. A non-sterile API may be dissolved in a non-aqueous vehicle and sterilized by filtration through a 0.22 µm or 0.2 µm sterilising-grade membrane. Filter compatibility testing per Ph Eur 5.1.1 is required to rule out adsorptive loss of amitraz or vehicle components. Terminal moist-heat sterilization is generally unsuitable in aqueous formulations because it accelerates hydrolysis; if terminal sterilization is attempted, the maximum time–temperature combination must be justified by degradant data.

For injectable or oral liquid preparations, pH is a critical variable. The hydrolysis of amitraz is acid-catalyzed; the free base is more stable in the non-ionized state above 5.0. A pH range of 5.5–6.5 is commonly screened for oral liquids, but the final pH must be defined by forced degradation and long-term stability studies. Buffer species should avoid nucleophilic amines, which may interact with the formamidine bridge and generate additional degradation products.

Residual solvents in injectable formulations must satisfy ICH Q3C parenteral limits, which are tighter than oral limits. The pharma-grade API is vacuum-dried, but each batch must be verified because solvent residues can be batch-dependent. Gas chromatographic headspace analysis per Ph Eur 5.4 is used, with method sensitivity validated below the permitted limit.

Amitraz should not be blended with strong oxidizing agents, strongly acidic excipients, or amine-functional additives that can react with the formamidine bridge. Storage of the API is recommended at controlled room temperature, protected from light and moisture, because exposure to humid air can increase water content above 0.5 % and promote hydrolysis. When relative humidity exceeds 60 %, pre-drying of excipients is advisable before dry granulation or direct compression.